News Press Releases
REDPOINT BIO RELOCATES CORPORATE HEADQUARTERS AND RESEARCH FACILITY
Ewing, New Jersey, May 21, 2007 – Redpoint Bio Corporation, a company developing compounds to improve the taste of pharmaceutical, food and beverage products, today announced that it has relocated its corporate headquarters and research facility to 7 Graphics Drive, Ewing, New Jersey, 08628. The Company’s new phone number is (609) 637-9700 and the fax number has been changed to (609) 637-0126. Redpoint Bio Corporation is a wholly owned subsidiary of Robcor Properties, Inc. (OTCBB:RBCR).
Commenting on today’s news, Ray Salemme, Ph.D., Chief Executive Officer of Redpoint Bio, noted, “Our new, state-of-the-art facility in Ewing, New Jersey is ideally suited to meet Redpoint’s needs and will enable us to move ahead with the planned build-out of our research and development operations.”
The owner of the property is BioMed Realty Trust, a real estate investment trust focused on providing real estate to the life science industry. The Global Life Science Practice of Cushman and Wakefield represented Redpoint in the lease negotiations.
Redpoint Bio’s new 18,577 square foot corporate facility will house the Company’s headquarters and research facilities, while allowing for future expansion. The building’s convenient location provides Redpoint Bio with continued access to key academic and scientific labor bases in New Jersey and Pennsylvania.
About Redpoint Bio
Redpoint Bio is leveraging recent discoveries in the molecular biology of taste to discover and develop novel taste enhancers and aversive taste blockers for the food, beverage and pharmaceutical industries. Redpoint’s food and beverage program is focused on identifying flavor enhancers that improve the taste of existing ingredients, reduce the need for excess sugar and salt, and contribute to the development of healthier, better-tasting foods and beverages. The pharmaceutical program uses a biochemical approach aimed at suppressing the bitterness of medicines, which has the potential to expand the range of formulation options and increase patient compliance. For more information, please visit the Company’s website at www.redpointbio.com.
Safe Harbor Statement
In addition to historical facts or statements of current condition, this press release contains forward-looking statements within the meaning of the "Safe Harbor" provisions of The Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company’s current expectations or forecasts of future events. The Company’s performance and financial results could differ materially from those reflected in these forward-looking statements due to among other factors, any efforts by third parties to invalidate or limit any patents, the marketplace acceptance of its products, the decisions of regulatory authorities, the results of clinical trials and general financial, economic, regulatory and political conditions affecting the food, biotechnology and pharmaceutical industries generally. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. The Company undertakes no obligation to update publicly any forward-looking statement.
CONTACT AT:
Redpoint Bio:
Scott Horvitz
Chief Financial Officer
(609) 637-9700, ext. 207
At Rx Communications Group (for Redpoint Bio):
Melody Carey (investors): (917) 322-2571
Paula Schwartz (investors): (917) 322-2216
Tina Posterli (media): (917) 322-2565
Redpoint Bio
